Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zidesamtinib in advanced ROS1+ NSCLC and other solid tumors
NCT05118789Phase 2Recruiting
- Sponsor
- Nuvalent
- Start
- Jan 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 2 trial of zidesamtinib in non-small cell lung cancer (NSCLC), solid tumor, sponsored by Nuvalent. Started Jan 2022; status: recruiting.
02
Drugs
zidesamtinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT05118789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118789.